Gilead Sciences, Inc. v. Natco Pharma Limited, No. 13-1418 (Fed. Cir. Apr. 22, 2014)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Gilead Sciences, Inc. (“Gilead”) owns United States Patent Nos. 5,763,483 and 5,952,375, which are directed to antiviral compounds and methods for their use. While the patents list the same inventors and the written d e- scriptions disclose similar content, they do not claim priority to a common patent application and have diffe r- ent expiration dates.